Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.31M Buy
41,328
+468
+1% +$54.8K 2.53% 4
2026
Q1
$4.92M Sell
40,860
-20,740
-34% -$2.39M 2.39% 4
2025
Q4
$6.48M Buy
61,600
+1,015
+2% +$95.3K 3.31% 1
2025
Q3
$5.08M Buy
60,585
+1,655
+3% +$136K 2.74% 2
2025
Q2
$4.66M Buy
58,930
+28,893
+96% +$2.3M 2.71% 3
2025
Q1
$2.7M Buy
30,037
+8,014
+36% +$748K 1.6% 28
2024
Q4
$2.19M Buy
22,023
+376
+2% +$38.8K 1.42% 31
2024
Q3
$2.46M Buy
21,647
+455
+2% +$54.1K 1.62% 28
2024
Q2
$2.62M Sell
21,192
-1,011
-5% -$130K 1.87% 20
2024
Q1
$2.93M Sell
22,203
-430
-2% -$53K 2.06% 19
2023
Q4
$2.47M Buy
22,633
+1,659
+8% +$172K 1.88% 23
2023
Q3
$2.18M Sell
20,974
-400
-2% -$43.1K 1.91% 24
2023
Q2
$2.26M Sell
21,374
-200
-0.9% -$22.7K 1.98% 21
2023
Q1
$2.3M Sell
21,574
-866
-4% -$93.5K 2.09% 17
2022
Q4
$2.49M Sell
22,440
-550
-2% -$56.2K 2.27% 15
2022
Q3
$1.98M Sell
22,990
-175
-0.8% -$15.6K 1.97% 21
2022
Q2
$2.11M Buy
23,165
+65
+0.3% +$5.76K 1.93% 25
2022
Q1
$2M Buy
23,100
+2,165
+10% +$171K 1.63% 28
2021
Q4
$1.6M Buy
+20,935
New +$1.67M 1.43% 31

Other funds holding MRK

Apricus Wealth's MRK Position: Q2 2026 in Review

Apricus Wealth increased its Merck (MRK) stake by 1.1% in Q2 2026, buying an estimated $54.8K and bringing the position to 41,328 shares worth $5.31M. The position accounts for 2.53% of the portfolio, ranked #4.

Apricus Wealth first reported a position in MRK in Q4 2021 and has held it in 19 quarters since. The position peaked at $6.48M in Q4 2025. 1,411 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Apricus Wealth held 41,328 shares of Merck worth $5.31M as of Q2 2026.
  • Apricus Wealth bought 468 Merck shares in Q2 2026, an estimated $54.8K.
  • Merck made up 2.53% of Apricus Wealth's portfolio in Q2 2026, its #4 holding.
  • Apricus Wealth first reported a position in Merck in Q4 2021 and has held it in 19 quarters since.
  • Apricus Wealth's Merck position peaked at $6.48M in Q4 2025.
  • 1,411 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Apricus Wealth's 13F filing for Q2 2026, filed 22 Jul 2026.